

MEDX HEALTH CORP.

Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2015 and 2014

(UNAUDITED)

(Presented in Canadian dollars)

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

The accompanying unaudited consolidated financial statements for MedX Health Corp. were prepared by management in accordance with International Financial Reporting Standards (IFRS). Management acknowledges responsibility for the preparation and presentation of the consolidated financial statements, including responsibility for significant accounting judgments and estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances. In the opinion of management, the unaudited consolidated financial statements have been prepared within acceptable limits of materiality and are in accordance with International Accounting Standard 34-Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established processes, which are in place to provide them sufficient knowledge to support management representations that they have exercised reasonable diligence that (i) the consolidated financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of and for the periods presented by the consolidated financial statements and (ii) the consolidated financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented by the consolidated financial statements.

The Board of Directors is responsible for reviewing and approving the consolidated financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the consolidated financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the consolidated financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

The unaudited Consolidated Financial Statements as at and for the three and six month periods ended June 30, 2015 and 2014 have not been reviewed by the Company's auditor.

MEDX HEALTH CORP.

Consolidated Statements of Financial Position
(Unaudited)
Presented in Canadian dollars

	June 30 2015	December 31 2014
ASSETS		
Current assets		
Cash	\$ 516,884	\$ 3,978
Accounts receivable (Note 3)	93,454	78,487
Inventory (Note 4)	173,534	137,110
Prepaid expenses and deposits, and other	23,096	46,438
	806,968	266,013
Property and equipment (Note 5)	62,926	71,710
Intangible assets (Note 6)	125,217	138,217
	\$ 995,111	\$ 475,940
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Note 7)	\$ 2,573,670	\$ 2,641,267
Deferred revenue	16,400	16,400
Demand loans (Note 8)	179,000	79,000
	2,769,070	2,736,667
Long-term debt (Note 8)	500,000	-
	3,269,070	2,736,667
EQUITY		
Share capital (Note 9)	15,309,259	15,309,259
Contributed surplus (Note 9)	3,103,959	3,010,550
Warrants (Note 9)	1,130,025	1,130,025
Deficit	(21,817,202)	(21,710,561)
	(2,273,959)	(2,260,727)
	\$ 995,111	\$ 475,940

Going concern (Note 1), Commitments and contingencies (Note 15)
See accompanying notes to the consolidated financial statements

MEDX HEALTH CORP.

Consolidated Statements of Comprehensive Loss

(Unaudited)

Presented in Canadian dollars

Three and Six Months ended June 30, 2015 and 2014

	Three Months Ended June 30		Six Months Ended June 30	
	2015	2014	2015	2014
Sales	\$ 367,256	\$ 220,019	\$ 665,875	\$ 377,791
Cost of sales	89,828	83,506	210,079	151,623
Gross profit	277,428	136,513	455,796	226,168
Expenses				
Selling, general and administrative	269,642	409,310	426,657	716,996
Share-based compensation (Note 9)	42,034	-	93,409	-
Interest	2,030	2,493	7,610	7,451
Loss (gain) on debt settlements (Note 9a)	-	(261,362)	-	(261,362)
Foreign exchange (gain) loss	3,439	(14,000)	12,977	21,597
Amortization of property and equipment	4,392	3,544	8,784	7,190
Amortization of intangibles	6,500	6,500	13,000	13,000
	328,037	146,485	562,437	504,872
Comprehensive loss for the period	\$ (50,609)	\$ (9,972)	\$ (106,641)	\$ (278,704)
Loss per share, basic and fully diluted	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average number of shares outstanding	70,637,072	67,452,266	70,637,072	64,056,770
See accompanying notes to consolidated financial statements				

MEDX HEALTH CORP.

Consolidated Statements of Changes in Equity
(Unaudited)
Presented in Canadian dollars

Six months ended June 30, 2015 and 2014

	Share Capital	Contributed Surplus	Warrants	Deficit	Total
Balance, December 31, 2013	\$ 14,705,250	\$ 2,611,976	\$ 792,295	\$ (21,505,984)	\$ (3,396,463)
Comprehensive loss for the period				(278,704)	(278,704)
Common shares issued on debt settlement	174,242				174,242
Common shares issued for cash	429,767		397,101		826,868
Balance, June 30, 2014	\$ 15,309,259	\$ 2,611,976	\$ 1,189,396	\$ (21,784,688)	\$ (2,674,057)
Balance, December 31, 2014	\$ 15,309,259	\$ 3,010,550	\$ 1,130,025	\$ (21,710,561)	\$ (2,260,727)
Comprehensive loss for the period				(106,641)	(106,641)
Share-based compensation		93,409			93,409
Balance, June 30, 2015	\$ 15,309,259	\$ 3,103,959	\$ 1,130,025	\$ (21,817,202)	\$ (2,273,959)

See accompanying notes to the consolidated financial statements

MEDX HEALTH CORP.Consolidated Statements of Cash Flows
(Unaudited)
Presented in Canadian dollars

Three and Six Months ended June 30, 2015 and 2014

	Three Months Ended June 30		Six Months Ended June 30	
	2015	2014	2015	2014
Cash flows from operating activities				
Comprehensive loss for the period	\$ (50,609)	\$ (9,972)	\$ (106,641)	\$ (278,704)
Adjustments for non-cash items				
Amortization of property and equipment	4,392	3,544	8,784	7,190
Amortization of intangible assets	6,500	6,500	13,000	13,000
Share-based compensation	42,034	-	93,409	-
Foreign exchange (gain)/loss	-	(14,000)	-	21,597
(Gain)/loss on debt settlements	-	(261,362)	-	(261,362)
	<u>2,317</u>	<u>(275,290)</u>	<u>8,552</u>	<u>(498,279)</u>
Net change in non-cash operating working capital items:				
Accounts receivable	(77,005)	(36,451)	(14,967)	5,157
Inventory	(44,672)	(14,294)	(36,424)	(30,753)
Prepaid expenses and deposits	11,641	(4,874)	23,342	(29,112)
Accounts payable and accrued liabilities	101,595	(22,406)	(67,597)	(241,684)
	<u>(8,441)</u>	<u>(78,025)</u>	<u>(95,646)</u>	<u>(296,392)</u>
Net cash used in operating activities	<u>(6,124)</u>	<u>(353,315)</u>	<u>(87,094)</u>	<u>(794,671)</u>
Cash flows from investing activities				
Purchases of property and equipment	-	(22,390)	-	(49,091)
Net cash used in investing activities	-	(22,390)	-	(49,091)
Cash flows from financing activities				
Proceeds from issuance (repayment) of Demand loans	-	(150,000)	100,000	(150,000)
Proceeds from issuance of long-term debt	500,000	-	500,000	-
Issuance of share capital, net of issue costs	-	326,443	-	826,868
Net cash from financing activities	<u>500,000</u>	<u>176,443</u>	<u>600,000</u>	<u>676,868</u>
Net change in cash for the period	<u>493,876</u>	<u>(199,262)</u>	<u>512,906</u>	<u>(166,894)</u>
Cash, beginning of period	<u>23,008</u>	<u>224,645</u>	<u>3,978</u>	<u>192,277</u>
Cash, end of period	\$ <u>516,884</u>	\$ <u>25,383</u>	\$ <u>516,884</u>	\$ <u>25,383</u>

See accompanying notes to consolidated financial statements

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

1. NATURE OF OPERATIONS AND GOING CONCERN

MedX Health Corp. ("MedX" or "the Company") is incorporated under the laws of Ontario. The Company develops, manufactures and markets skin related screening tools and phototherapy devices for pain relief and tissue repair throughout North America, Europe and Asia.

The Company's shares are listed on the TSX Venture Exchange under the symbol MDX. Its head office, principal address, and registered office is located at 1495 Bonhill Road, Unit #1, Mississauga, ON, L5T 1M2.

The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As at June 30, 2015, the Company had a working capital deficiency of \$1,962,102 (December 31, 2014 - \$2,470,654), had accumulated losses of \$21,817,202 (December 31, 2014 - \$21,710,561), and negative equity. These conditions indicate the existence of material uncertainties that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon achieving a profitable level of operations and obtaining additional financing, neither of which is assured. The Company has been able to raise capital to continue to market its products, and continues to develop sales opportunities that could result in additional sales of its product in the future. These consolidated financial statements do not give effect to any adjustments which might be necessary should the Company be unable to continue as a going concern and be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. These adjustments could be material.

2. SIGNIFICANT ACCOUNTING POLICIES

Statement of Compliance

These consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), effective for the reporting period ended June 30, 2015.

The policies applied in these consolidated financial statements are based on IFRS issued and outstanding as of August 28, 2015, the date these financial statements were authorized for issuance by the Board of Directors.

Basis of Presentation

These interim consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 "Interim Financial Reporting". The interim consolidated financial statements do not include all the information and disclosures required in the Company's annual financial statements and should be read in conjunction with the Company's annual consolidated financial statements for the year ended December 31, 2014.

These financial statements have been prepared on a historical cost basis. In addition, these financial statements have been prepared using the accrual basis of accounting.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements

At the date of authorization of these financial statements, the IASB and International Financial Reporting Interpretations Committee ("IFRIC") have issued the following new and revised Standards and Interpretations which are not yet effective.

The Company has not early adopted these standards, amendments and interpretations; however it is currently assessing what impact, if any, the application of these standards or amendments will have on future consolidated financial statements.

IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures were amended by the IASB in September 2014 to eliminate an inconsistency between IFRS 10 and IAS 28 in dealing with the sale or contribution of assets between an investor and its associate or joint venture. Subsequent to the amendments, a full gain or loss is recognized when a transaction involves a business (whether it is housed in a subsidiary or not) and a partial gain or loss is recognized when a transaction involves assets that do not constitute a business, even if these assets are housed in a subsidiary. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IFRS 10 Consolidated Financial Statements, IFRS 12 Disclosure of Interests in Other Entities and IAS 28 Investments in Associates and Joint Ventures were amended by the IASB in December 2014 to clarify the application of the requirement for investment entities to measure subsidiaries at fair value instead of consolidating them. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IFRS 11 Joint Arrangements was amended by the IASB in May 2014. The amendments add new guidance on how to account for the acquisition of an interest in a joint operation that constitutes a business. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IFRS 14 Regulatory Deferral Accounts, an interim standard, was issued by the IASB in January 2014 and permits first-time adopters to continue to recognize amounts related to rate regulation in accordance with previous GAAP requirements when they adopt IFRS. The standard requires that the effect of rate regulation must be presented separately from other items. An entity that already presents IFRS financial statements is not eligible to apply the Standard. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IAS 1 Presentation of Financial Statements was amended by the IASB in December 2014. The amendments are designed to further encourage companies to apply professional judgement in determining what information to disclose in their financial statements. For example, the amendments make clear that materiality applies to the whole of financial statements and that the inclusion of immaterial information can inhibit the usefulness of financial disclosures. Furthermore, the amendments clarify that companies should use professional judgement in determining where and in what order information is presented in the financial disclosures. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IAS 16 Property, Plant and Equipment and IAS 38 Intangible Assets were amended by the IASB in May 2014. Amendments clarify that the use of revenue-based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. The IASB also clarified that revenue is generally presumed to be an inappropriate basis for

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements (continued)

measuring the consumption of the economic benefits embodied in an intangible asset. This presumption, however, can be rebutted in certain limited circumstances. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IAS 16 Property, Plant and Equipment and IAS 41 Agriculture were amended by the IASB in June 2014. Amendments include bringing bearer plants within the scope of IAS 16, instead of IAS 41, because their operation is similar to that of manufacturing. The produce growing on bearer plants will remain within the scope of IAS 41. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IAS 27 Separate Financial Statements was amended by the IASB in August 2014 to allow entities to use the equity method to account for investments in subsidiaries, joint ventures and associates in their separate financial statements. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

IFRS 15 Revenue from Contracts with Customers was issued by the IASB in May 2014. The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard will also result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements. Earlier application is permitted. IFRS 15 supersedes the following standards: IAS 11 Construction Contracts, IAS 18 Revenue, IFRIC 13 Customer Loyalty Programmes, IFRIC 15 Agreements for the Construction of Real Estate, IFRIC 18 Transfers of Assets from Customers, and SIC-31 Revenue—Barter Transactions Involving Advertising Services. The amendment is effective for annual periods beginning on or after January 1, 2017.

IFRS 9 Financial Instruments was issued by the IASB in July 2014 and will replace IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. A new hedge accounting model is introduced and represents a substantial overhaul of hedge accounting which will allow entities to better reflect their risk management activities in the financial statements. The most significant improvements apply to those that hedge non-financial risk, and so these improvements are expected to be of particular interest to non-financial institutions. The amendment is effective for annual periods beginning on or after January 1, 2017. Earlier application is permitted.

Consolidation

These consolidated financial statements include the accounts of MedX Health Corp. and its wholly-owned subsidiaries, MedX Electronics Inc., and LaserPath Therapeutics Inc. All inter-company transactions and balances between the consolidated entities have been eliminated. During 2014, the Company disposed of the shares and other interests in a number of inactive subsidiaries, including

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Consolidation (continued)

Health Care North Inc., MedX Health Inc., and 1419671 Ontario Limited, for nil consideration (Note 11).

Income taxes

Income tax expense represents the sum of current income taxes and deferred income taxes. Current and deferred taxes are recognized in profit and loss, except to the extent that it relates to items recognized in other comprehensive loss or directly in equity. Under these circumstances, the taxes are recognized in other comprehensive loss or directly in equity.

Current income taxes -

Current income tax assets and liabilities for the current and prior years are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute current income tax assets and liabilities are measured at tax rates, which have been enacted or substantively enacted at the reporting date. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to set off the amounts, and the Company intends to settle on a net basis, or to realize the asset and settle the liability simultaneously.

Deferred income taxes -

Deferred income taxes are provided using the asset and liability method applied to temporary differences at the date of the statement of financial position between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

- Where the deferred income tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, and carry forward of unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax losses can be utilized except:

- Where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred income tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Income taxes (continued)

The carrying amount of deferred income tax assets is reviewed at each date of the statement of financial position and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each date of the statement of financial position and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the date of the statement of financial position.

Deferred income tax assets and deferred income tax liabilities are offset if, a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend to either settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Share-based payment transactions

Employees, directors and service providers of the Company may receive a portion of their compensation in the form of share-based payment transactions, whereby services are rendered as consideration for equity instruments ("equity-settled transactions").

In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment.

Equity settled transactions

The costs of equity settled transactions are measured by reference to the fair value of the equity instrument at the date on which they are granted.

The costs of equity settled transactions are recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant party becomes fully entitled to the award ("the vesting date"). The cumulative expense is recognized for equity settled transactions at each reporting date until the vesting date, and reflects the Company's best estimate of the number of equity instruments that will ultimately vest. The profit or loss charge or credit for a period represents the movement in cumulative expense recognized as at the beginning and end of that period and the corresponding amount is represented in contributed surplus.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Equity settled transactions (continued)

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether or not the market condition is satisfied provided that all other performance and/or service conditions are satisfied.

Comprehensive income (loss) per share

Where the terms of an equity settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified. An additional expense is recognized for any modification which increases the total fair value of the share based payment arrangement, or is otherwise beneficial to the employee as measured at the date of modification.

The dilutive effect of outstanding options and warrants is reflected as additional dilution in the computation of earnings per share.

Income (loss) per share and comprehensive income (loss) per share are based on the weighted average number of common shares outstanding for the period. In a period when the Company reports a loss and comprehensive loss, the effect of potential issuances of shares under options and warrants outstanding would be anti-dilutive and, therefore basic and diluted loss and comprehensive per share are the same.

Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. The increase in the provision due to passage of time is recognized as interest expense.

Significant Accounting Judgments and Estimates

The preparation of financial statements requires management to make judgments, estimates and form assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities at the date of the financial statements and reported amount of revenues and expenses during the reporting period. Estimates and underlying assumptions are reviewed on an ongoing basis. Significant areas requiring the use of management estimates relate to going concern, the valuation and determination of the useful lives of assets, valuation of share-based compensation, warrants, share capital, debt settlements through issuance of shares, deferred income taxes, deferred revenue, receivables and inventory valuation, and the valuation of intangibles of the Company. Management believes that the estimates utilized in preparing its consolidated financial statements are reasonable and prudent; however, actual results may differ from those estimates.

Financial instruments

Financial assets

All financial assets are initially recorded at fair value and designated upon inception into one of the

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial instruments (continued)

Financial assets (continued)

following four categories: held-to-maturity, available-for-sale, loans-and-receivables or at fair value through profit or loss ("FVTPL"). Financial assets classified as FVTPL are measured at fair value with unrealized gains and losses recognized through operations.

Financial assets classified as loans-and-receivables and held-to-maturity are measured at amortized cost.

Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income (loss) except for losses in value that are considered other than temporary.

Transactions costs associated with FVTPL financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period.

Financial liabilities classified as FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as FVTPL. Derivatives, including separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Fair value changes on financial liabilities classified as FVTPL are recognized through the statement of comprehensive income.

The Company has elected to apply the following classifications to each of its significant categories of financial instruments:

Asset/Liability	Category	Measurement
Cash	Fair value through profit or loss	Fair value
Accounts receivable	Loans and receivables	Amortized cost
Accounts payable and accrued liabilities		Amortized cost
Demand Loans	Other financial liabilities	Amortized cost

Foreign currency

a. Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its wholly-owned subsidiaries. Translations required in these consolidated financial statements are in accordance with IAS 21, The Effects of Changes in Foreign Exchange Rates.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Foreign currency (continued)

b. Foreign currency transactions

Foreign currency monetary assets and liabilities are translated into the entity's functional and presentation currency using the closing rate at the end of each reporting period. Non-monetary assets and liabilities are translated at the rates on the date the fair value was determined or at historical cost using the rate at the date of the transaction. Translation gains and losses are included in the consolidated statement of comprehensive income (loss).

Revenue recognition

The Company recognizes revenue when it is realized or earned. The Company considers revenue realized or earned on the sale of goods when persuasive evidence of a sale arrangement exists, title and risk of product ownership is transferred to the customer, collection of the revenue is reasonably assured and the price is reasonably determinable. Remuneration in the form of non-monetary consideration is recognized on the basis of fair value of consideration given up or fair value of consideration received, whichever is more reliable. Provisions are established for estimated warranty costs on applicable product sales at the time revenue is recognized. Cash received in advance of meeting these revenue recognition criteria is recorded as deferred revenue.

Consulting revenue is recognized as services are provided.

Revenue from licensing the Company's technology, or from maintenance contracts is recognized over the period covered by the license or contract. Amounts received and not yet recognized are included in deferred revenue.

Cash and cash equivalents

Cash and cash equivalents includes cash on hand and short-term, highly liquid investments with maturities when acquired of less than three months, held for purposes of meeting short-term cash requirements. There are currently no cash equivalents.

Inventories

Raw materials, work-in-process and finished goods inventories are stated at the lower of cost and net realizable value, with cost determined on a weighted average basis. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale. Finished goods and work-in-process inventory costs include raw materials, direct labour and allocation of overheads. A provision for shrinkage and obsolescence is calculated based on historical experience. Management reviews the entire provision to assess whether, based on economic conditions, it is adequate.

Property and equipment

Property and equipment are recorded at cost net of accumulated depreciation and write-downs for impairment, if any. Depreciation is calculated using the declining balance method over their estimated useful lives at the following annual rates:

Furniture	-	20%
Computers	-	30%
Manufacturing equipment	-	20% - 30%

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

2. SIGNIFICANT ACCOUNTING POLICIES (continued)

Intangible assets

Patents and other intangibles are recorded at cost, net of accumulated amortization and write-downs for impairment. On the basis they have a finite useful life, they are amortized on a straight line basis over their estimated useful life which management generally estimates at 5 - 20 years.

Impairment of non-financial assets

At each reporting date of the consolidated statement of financial position, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is an indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the assets belong.

The recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the consolidated statement of comprehensive income (loss), unless the relevant asset is carried at a re-valued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years.

3. ACCOUNTS RECEIVABLE

The amount of accounts receivable is net of an allowance for doubtful accounts, which was \$nil at June 30, 2015 (December 31, 2014 - \$nil).

4. INVENTORY

	June 30 2015	December 31 2014
Raw materials	\$ 63,714	\$ 35,029
Work-in-process	5,593	5,187
Finished goods	104,227	96,894
	\$ 173,534	\$ 137,110

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

5. PROPERTY AND EQUIPMENT

	Furniture	Computers	Manufacturing Equipment	Total
Cost				
Balance, December 31, 2013	\$ 85,186	\$ 58,231	\$ 55,973	\$ 199,390
Disposals	(13,118)	(36,430)	(37,210)	(86,758)
Additions	15,418	1,873	33,800	51,091
Balance, December 31, 2014	\$ 87,486	\$ 23,674	\$ 52,563	\$ 163,723
Balance, June 30, 2015	\$ 87,486	\$ 23,674	\$ 52,563	\$ 163,723
Accumulated Amortization				
Balance, December 31, 2013	\$ 75,887	\$ 53,135	\$ 35,170	\$ 164,192
Disposals	(13,118)	(36,430)	(37,210)	(86,758)
Amortization	3,419	2,317	8,843	14,579
Balance, December 31, 2014	\$ 66,188	\$ 19,022	\$ 6,803	\$ 92,013
Amortization	2,139	696	5,949	8,784
Balance, June 30, 2015	\$ 68,327	\$ 19,718	\$ 12,752	\$ 100,797
Carrying Value				
Balance, December 31, 2014	\$ 21,298	\$ 4,652	\$ 45,760	\$ 71,710
Balance, June 30, 2015	\$ 19,159	\$ 3,956	\$ 39,811	\$ 62,926

6. INTANGIBLES

In 2011, the Company purchased the worldwide assets related to a technology called SIAscopy™, which is used to help gather information about suspicious moles and lesions, helping physicians and patients to come to a more informed decision about the diagnosis of skin disorders. The assets acquired included the patents, trademarks, manufacturing procedures, software, inventory, and equipment, existing distribution, supply and other contracts previously entered into by the seller.

	SIAscopy
Cost	
Balance, December 31, 2014	\$ 241,699
Balance, June 30, 2015	\$ 241,699
Accumulated Amortization	
Balance, December 31, 2013	\$ 77,482
Amortization	26,000
Balance, December 31, 2014	103,482
Amortization	13,000
Balance, June 30, 2015	\$ 116,482
Carrying Value	
Balance, December 31, 2014	\$ 138,217
Balance, June 30, 2015	\$ 125,217

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are principally comprised of amounts outstanding for trade purchases relating to general and administrative expenses, accrued salaries and Board fees, unpaid payroll and sales taxes, and interest.

	June 30 2015	December 31 2014
Accounts payable	\$ 657,200	\$ 739,054
Amounts owing to staff, officers and board of directors	1,135,340	1,160,415
Taxes, including unpaid payroll withholdings and related interest, accrued sales and other taxes	413,192	393,140
Other accrued liabilities	367,938	348,658
	\$ 2,573,670	\$ 2,641,267

8. DEMAND LOANS AND LONG-TERM DEBT

During 2015, the Company entered into a demand loan arrangement with a corporation controlled by a director, and was advanced \$100,000, with no fixed terms for repayment, without interest, but subject to a 3% commitment fee, together with the grant, subject to the Company first obtaining all relevant regulatory and other consents and approvals, of a Warrant to purchase 100,000 shares from the treasury of the Company at the price of \$0.12 per share, valid for a period of two years.

During 2015, the Company entered into a \$500,000 term loan with a party that is related to a director of the Company. The loan is for three years, with an 8% interest rate, paid quarterly, and no principal payments to maturity. The Company has the option to repay the loan at any time without penalty. The lender has the option of requiring the principal portion to be repaid in monthly installments to maturity, if certain financial targets are not being met. The debt is secured by a general security agreement.

The Company issued a demand loan in 2014 of \$50,000 from a corporation controlled by a director, which is non-interest bearing.

A demand loan of \$29,000 with a party related to a director of the Company bears interest at prime plus 6% per annum, with interest accrued to June 30, 2015.

In 2014, a \$25,000 demand loan with a director was settled in exchange for common shares, as described in note 9(a). The interest rate on the loan was 10% per annum, and a portion of the accrued interest was included in the settlement.

A \$150,000 promissory note issued in May 2013, bearing interest at 10% per annum, was repaid during 2014, along with \$15,000 of accrued interest, from the proceeds of a share offering.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

9. SHARE CAPITAL

Common Shares

Authorized - Unlimited number of common shares

Issued and outstanding

	Number of shares	Stated Capital
Outstanding at December 31, 2013	59,744,657	\$ 14,705,250
Issued in exchange for debt (a)	1,742,415	174,242
Issued for cash (b)	9,150,000	429,767
Outstanding at December 31, 2014	70,637,072	\$ 15,309,259
Outstanding at June 30, 2015	70,637,072	\$ 15,309,259

a) Shares issued in exchange for debt

During 2014, the Company issued 1,742,415 common shares to settle \$435,604 of amounts owing to insiders of the Company. The market value of the Company's shares as of the date of issue was \$0.10, resulting in an addition to share capital of \$174,242, and a gain on the debt settlement of \$261,362. Included in the settled debt was a demand loan of \$25,000, with the remainder representing unpaid interest, salary, director and other fees.

b) Shares issued for cash

During 2014, the Company completed the following issues of shares:

- On March 19, 2014, the Company issued the first tranche of a brokered private placement of 5,650,000 units (the "Units") for gross proceeds of \$565,000 at \$0.10 per Unit. Each Unit consisted of one common share and one common share warrant of the Company. Each warrant entitles the holder to purchase one common share of the Company for \$0.20 per share until March 19, 2016.

The Company allocated the \$565,000 proceeds between the shares and the warrants issued, based on the relative value of the components. The value of the shares was based on the closing value of the Company's shares on the closing date of \$0.12, and the value for the warrants using the Black-Scholes pricing model at the issue date as \$0.083 per share based on a share price volatility of 166% based on historical volatility, a risk free rate of 1.06%, and with no expected dividend yield over the life of the warrant. As a result, the amount was allocated as to \$333,209 to share capital and \$231,791 to warrants. The Company incurred cash related issue costs in connection with private placement of \$64,575, and this has been allocated in the same manner as the proceeds, with \$38,083 as a reduction of share capital and \$26,492 as a reduction of the warrants.

The Company issued 452,000 broker warrants in connection with the private placement. The value of the broker warrants, determined as \$80,175, are considered as issue costs of the private placement, and this amount has been allocated in the same manner as the proceeds, with \$47,283 as a reduction of share capital and \$32,892 as a reduction of the warrants. Each broker warrant consists of a right to purchase a unit comprising one common share and one common share warrant, and the unit can be purchased for \$0.10 until March 19, 2016. The warrant included in the unit allows the holder to acquire one common share for \$0.20 until March 19, 2016. The value for the broker warrants was

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

9. SHARE CAPITAL (continued)

b) Shares issued for cash (continued)

determined using the Black-Scholes pricing model with a share price volatility of 166% based on historical volatility, a risk free rate of 1.06%, and with no expected dividend yield over the life of the warrants.

- On May 9, 2014, the Company issued the second tranche of a brokered private placement of 3,500,000 units (the "Units") for gross proceeds of \$350,000 at \$0.10 per Unit. Each Unit consisted of one common share and one common share warrant of the Company. Each warrant entitles the holder to purchase one common share of the Company for \$0.20 per share until May 9, 2016.

The Company allocated the \$350,000 proceeds between the shares and the warrants issued, based on the relative value of the components. The value of the shares was based on the closing value of the Company's shares on the closing date of \$0.10, and the value for the warrants using the Black-Scholes pricing model at the issue date as \$0.068 per share based on a share price volatility of 167% based on historical volatility, a risk free rate of 1.13%, and with no expected dividend yield over the life of the warrant. As a result, the amount was allocated as to \$208,708 to share capital and \$141,292 to the warrants. The Company incurred cash related issue costs in connection with private placement of \$23,557, which has been allocated in the same manner as the proceeds, with \$14,047 as a reduction of share capital and \$9,510 as a reduction of the warrants.

The Company issued 148,000 broker warrants in connection with the private placement. The value of the broker warrants, determined as \$21,359, are considered as issue costs of the private placement, and this amount has been allocated in the same manner as the proceeds, with \$12,737 as a reduction of share capital and \$8,622 as a reduction of the warrants. Each broker warrant consists of a right to purchase a unit comprising one common share and one common share warrant, and the unit can be purchased for \$0.10 until May 9, 2016. The warrant included in the unit allows the holder to acquire one common share for \$0.20 until May 9, 2016. The value for the broker warrants was determined using the Black-Scholes pricing model with a share price volatility of 167% based on historical volatility, a risk free rate of 1.13%, and with no expected dividend yield over the life of the warrants.

c) Warrants

The Company has issued warrants in connection with debt and share offerings and debt settlements. The value of warrants has been estimated in each case using the Black-Scholes pricing model as of the applicable date of the transaction. The number of warrants outstanding as of June 30, 2015 are summarized as follows:

	Exercise Price	Warrants	\$
Debt settlements – July 10, 2013	\$0.30	1,810,390	127,941
Debt settlements – November 14, 2013	\$0.30	6,026,722	604,983
Private Placement – March 19, 2014	\$0.20	5,650,000	172,407
Private Placement – March 19, 2014 - broker warrants	\$0.10 - \$0.20	452,000	80,175
Private Placement – May 9, 2014	\$0.20	3,500,000	123,160
Private Placement – May 9, 2014 - broker warrants	\$0.10 - \$0.20	148,000	21,359
		17,587,112	1,130,025

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

9. SHARE CAPITAL (continued)

c) Warrants (continued)

In connection with the settlement of the debt in July, 2013, the Company issued 1,810,390 warrants. Each warrant entitles the holder to purchase one common share of the Company for \$0.30 until December 31, 2015.

In connection with the settlement of debt in November, 2013, the Company issued 6,026,722 warrants. Each warrant entitles the holder to purchase one common share of the Company for \$0.30 until December 31, 2015.

In connection with the private placement completed in March, 2014, the Company granted 5,650,000 warrants, each allowing the holder to purchase one common share at a price of \$0.20 per share until March 19, 2016.

In connection with the private placement completed in March, 2014, the Company granted 452,000 broker warrant Units, and at a cost of \$0.10 per Unit until March 19, 2016, the holder receives one common share and the ability to purchase an additional common share at a price of \$0.20 per share, until March 19, 2016.

In connection with the private placement completed in May, 2014, the Company granted 3,500,000 warrants, each allowing the holder to purchase one common share at a price of \$0.20 per share until May 9, 2016.

In connection with the private placement completed in May, 2014, the Company granted 148,000 broker warrant Units, and at a cost of \$0.10 per Unit until May 9, 2016, the holder receives one common share and the ability to purchase an additional common share at a price of \$0.20 per share, until May 9, 2016.

d) Stock options

On June 24, 2014, the shareholders of the Company approved the establishment of a new Incentive Stock Option Plan. The new plan increased the number of options available under the plan from 5,076,332 to 12,000,000.

Under the terms of the plan, directors, officers, employees and consultants, subject to certain conditions, may be granted options to purchase common shares of the Company, and options granted under the old plan are carried forward to the new plan. As at June 30, 2015 there were 10,025,000 options that have been granted and are outstanding, with 1,975,000 options available to be granted under the plan. Options generally expire after five years, with vesting provisions stated in the plan.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

9. SHARE CAPITAL (continued)

d) Stock options (continued)

Activity in the Company's stock option plan for the period ended June 30, 2015 and the year ended December 31, 2014 is summarized as follows:

	Six months Ended June 30, 2015		Year ended December 31, 2014	
	Weighted- Average Exercise Number of Options	Price \$	Number of Options	Weighted- Average Exercise Price \$
Outstanding, beginning of period	10,025,000	0.10	4,450,000	0.10
Granted	-		7,150,000	0.10
Expired/forfeited	-		(1,575,000)	0.10
Outstanding, end of period	10,025,000	0.10	10,025,000	0.10

Of the options outstanding as of June 30, 2015, 8,390,129 may be exercised. All of the outstanding options have an exercise price of \$0.10, and an average remaining life of 3.8 years.

On November 29, 2014, 7,150,000 incentive stock options were granted, of which 5,515,129 are vested, with the remainder vesting by May, 2016. The options are exercisable at \$0.10 for a period of five years from the date of grant. The options granted were valued at \$490,211, of which \$339,203, representing the value of the options that vested during 2014, and \$93,409 during the six months ended June 30, 2015, was included in expenses, determined using the Black-Scholes option pricing model based on a risk-free interest rate of 2.00%, volatility of 211% based on historical stock price volatility, expected life of 5 years, and expected dividend yield of 0%.

10. INCOME TAXES

As of December 31, 2014, the Company had non-capital losses, carried forward of approximately \$4,461,843 (2013 – \$10,686,553) available to reduce future years' taxable income. These losses will expire as follows:

Expiry	
2015	\$ 7,600
2026	553,339
2027	101,131
2028	320,518
2029	1,418,650
2030	481,214
2031	324,117
2032	392,684
2033	638,392
2034	224,198
	<u>\$ 4,461,843</u>

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

11. DISPOSAL OF SUBSIDIARIES

The Company disposed of the shares and all other interests in several inactive subsidiaries on December 30, 2014, for nil consideration. The subsidiaries had been inactive for a number of years, had no assets, and liabilities of \$122,621. The Company recorded a gain on disposal of \$122,621 in the financial statements for the year ended December 31, 2014.

12. GEOGRAPHICAL AND CUSTOMER INFORMATION

The Company's products are sold on a worldwide basis. Sales for the six months ended June 30, 2015 were made to customers in the following geographic regions: Canada – 19%; United States – 20%, Rest of World – 61% (Year ended December 31, 2014: Canada – 28%; United States – 34%, Rest of World – 38%).

Approximately 47% of the Company's revenue for the six months ended June 30, 2015 was from two customers (Year ended December 31, 2014 - Two customers represented 31% of revenue).

13. FINANCIAL INSTRUMENTS

The Company has classified its financial instruments in accordance with IFRS into various categories as described in its accounting policies. A disclosure of exposures to risk with respect to financial instruments and the potential impact is described below.

Fair Value

The carrying value of accounts receivable, accounts payable and accrued liabilities, and demand loans approximates fair value due to the relatively short-term maturity of these financial instruments. Given the respective designations cash is the only financial instrument carried at fair values and has been categorized as level 1 on the fair value hierarchy.

The main risks the Company's financial instruments are exposed to are credit risk, interest rate risk, foreign currency risk and liquidity risk, each of which is discussed below.

Credit Risk -

Credit risk is low with respect to its trade and other receivables. Individual sales are relatively small, are normally to established customers, and often include a deposit for a large portion of the sale. Risk with respect to its cash is minor given the relatively small balances.

The company maintains cash balances with Canadian commercial banks. As such, the Company believes its credit risk is minimal on cash balances.

Interest Rate Risk-

The Company has a low exposure to risk with respect to interest rate fluctuations, as the level of interest-bearing debt is minor, and most of the debt is at a fixed rate of interest. A 1% change in interest rates would have a negligible impact on income. The Company may increase debt levels depending on the nature of the financing in the future. If cash balances are higher than required for immediate requirements, the Company invests with a low risk strategy in secure short-term deposits through major banks to earn interest income. The Company has no cash equivalents.

Foreign Currency Risk -

The Company has low exposure to foreign exchange fluctuations with respect to cash, given the low cash balances. There is an impact on comprehensive income from the translation of the accounts receivable and accounts payable balances as of the end of the period. The company sells its

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

13. FINANCIAL INSTRUMENTS (continued)

Fair Value (continued)

products internationally, and incurs costs from international suppliers. As of June 30, 2015, a portion of the Company's accounts receivable and accounts payable were denominated in US Dollars, Euros and British Pounds. A 5% change in the exchange rate of those currencies would impact the comprehensive income (loss) by approximately \$13,200.

The objective in managing foreign exchange risk is to monitor expenditure requirements in the short and medium term by currency, and convert available cash to the appropriate currency to match the requirements. Cash balances are small, and foreign exchange hedging is not appropriate.

Liquidity risk -

Liquidity risk results from an excess of financial liabilities over available financial assets at any point in time. The Company's objective in managing risk is to ensure that it raises the amount of cash required to fund operating losses and to maintain cash to meet its other obligations. In this regard, the Company has had difficulty raising the level of cash required to meet its financial obligations as they have come due, and has entered into a number of transactions to settle debts through the issuance of shares. Cash has been raised in the last several years, and the Company will be required to raise additional cash to fund its ongoing operating requirements. A portion of the cash raised was in the form of debt, due on a demand basis. The Company is in a position where its financial liabilities are greater than its assets.

14. CAPITAL MANAGEMENT

The Company defines its managed capital as the total of demand loans, long-term debt, and shareholders' deficiency including capital stock, warrants, contributed surplus and deficit. As at June 30, 2015, total managed capital was \$(1,594,959) compared with \$(2,181,727) as at December 31, 2014.

The Company's objectives when managing capital are:

- i. To maintain balance sheet strength, ensuring the Company's strategic objectives are met, while retaining an appropriate amount of leverage;
- ii. And, to provide an appropriate return to shareholders relative to the risk of the Company's underlying assets.

The Company manages its capital structure within guidelines approved by the Board of Directors. The Company makes adjustments to its capital structure based on changes in economic conditions and Company's planned requirements. The Company has the ability to adjust its capital structure by issuing new equity or debt, selling assets to reduce debt, controlling the amount it distributes to shareholders, and making adjustments to its capital expenditure program.

There were no changes in the Company's approach to capital management during the period ended June 30, 2015. The Company is not subject to externally imposed capital restrictions.

MEDX HEALTH CORP.

Notes to the Consolidated Financial Statements
For the Three and Six Months Ended June 30, 2015 and 2014
(Unaudited)
Presented in Canadian dollars

15. COMMITMENTS AND CONTINGENCIES

Under the terms of the agreement to acquire the SIAscopy™ assets in 2011, the Company is required to pay a royalty of 10% to the Seller on all future revenue related to the acquired assets.

The Company leases space for its office and manufacturing facility, with the current lease ending in August 2015, with all remaining rent having been prepaid.

Claims have been made against the Company in the normal course of its activities, including:

- The Company received notification in December, 2011 of a claim from a vendor for non-payment of goods delivered to the Company, amounting to 35,345 Euros. The Company is defending the claim, and has entered a counterclaim.
- The Company received notification In November, 2010 from a former employee disputing amounts due relating to his position as Chief Technology Officer, claiming approximately \$418,000 in damages. The Company has filed a counterclaim for breach of contract.

Although the outcome of these claims cannot be determined with certainty, management estimates that any potential payments resulting from their outcomes are not likely to have a substantial negative impact on the Company's results and financial position.

16. RELATED PARTY TRANSACTIONS

During the six months ended June 30, 2015 the Company incurred costs for management and Board compensation, prior to the reductions noted below, of \$248,000 (2014 - \$286,083) under the terms of their compensation arrangements, of which \$173,000 was not paid. In addition, \$79,123 of the expense recorded in 2015 for share-based compensation relates to management.

During 2015, certain members of the Board of Directors agreed to a reduction of \$134,000 of certain amounts owing to them, and the settlement for the remaining \$51,200 of such remaining amounts by the issuance of 512,500 shares of the Company, subject to all relevant regulatory and other consent and approval.

See notes 8 and 9 for related party transaction disclosure relating to demand loans, long-term debt, debt settlements, and stock options issuances.

Included in accounts payable and accrued liabilities as of June 30, 2015 is \$1,024,202 (December 31, 2014 - \$1,047,910) due to officers and directors of the Company.